Stocktoria

REVVITY, INC. RVTY

NYSE · stock · Laboratory Analytical Instruments · website · IPO 1965-07-06 · LEI

REVVITY, INC. (RVTY) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.26% (safety: safe). FY2025 revenue was $2.9B at a 8.4% net margin.

Chart by TradingView
66/100
Stocktoria Quality Score · grade B
6/9
Piotroski F — financial health
3.86
Altman Z″ — distress risk · safe
0.2%
Dividend yield 5y avg · safe · Dividend payout 13.6%

Quality score trend · recomputed for each fiscal year

Piotroski F /9
7 2 7 6 7 5 5 5 7 6 2017201720182019202120222023202320242025
Altman Z″
4.04 2.60 3.09 3.18 3.58 3.01 3.45 3.70 4.33 3.86 2017201720182019202120222023202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$117.88 as of 2026-08-01 · +30.8% 1y
$86.62$117.8852-wk
Market cap USD$12.6B
P / E52.3×
Dividend yield 5y avg0.2%
Net margin 5y avg17%
Return on equity 5y avg7.3%
Beta1.07
Employees11,000

Analyst price target

$121.07 +2.7% vs last
consensus: buy · 15 analysts
target range $100.00 – $145.00 · median $122.00
6 buy · 11 hold
Recent analyst actions
DateFirmRating
2026-08-05Evercore ISI GroupOutperform (main)
2026-07-06Evercore ISI GroupOutperform (main)
2026-05-07BarclaysEqual-Weight (main)
2026-05-06JP MorganNeutral (main)
2026-05-06TD CowenBuy (main)
2026-05-06StifelHold (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$5.89
Forward P / E20×
Next ex-dividend2026-10-23

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 76%
Return on equitystronger than 63%
Revenue growthstronger than 46%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.075
Retained earnings / assets0.498
EBIT / assets0.029
Equity / liabilities1.474

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
RVTYREVVITY, INC.6/93.8652.3+3.7%
BIOBIO-RAD LABORATORIES, INC.5/96.5410.7+0.7%
WATWATERS CORP /DE/4/91055.1+7%
BRKRBRUKER CORP4/92.98+2.1%
MTDMETTLER TOLEDO INTERNATIONAL INC/5/929.4+4%
ILMNILLUMINA, INC.7/93.0431.4-0.7%
TXG10x Genomics, Inc.4/91.63+5.2%

All Manufacturing companies →

About REVVITY, INC.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

FAQ

Is RVTY financially healthy?

REVVITY, INC.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does RVTY pay a dividend, and is it safe?

Yes. REVVITY, INC. pays a dividend yielding about 0.26% with a 13.6% payout ratio, rated “safe” for safety.

How profitable is RVTY?

In FY2025, REVVITY, INC. had a net margin of 8.4% and a return on equity of 3.3%.

Is RVTY overvalued or undervalued?

REVVITY, INC. trades at about 56.9× trailing earnings — above its 10-year norm (10-year range 19.3×–57.3×, median 30.6×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for RVTY?

The average Wall-Street price target for REVVITY, INC. is $121.07, about 2.7% above the recent price, from 15 analysts (consensus: buy).

Is RVTY a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on REVVITY, INC.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 52.3×, a dividend yield of 0.26%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-28. Facts plus Stocktoria's own computed scores — not investment advice.